Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases
Sign Up to like & getrecommendations! Published in 2024 at "Medicine"
DOI: 10.1097/md.0000000000038174
Abstract: Camrelizumab, donafenib, and transarterial chemoembolization (TACE) are recommended for advanced hepatocellular carcinoma (HCC), but their combined efficacy remains unclear. From July 2021 to January 2023, 20 Barcelona Clinic Liver Cancer stage C HCC patients were… read more here.
Keywords: donafenib; hepatocellular carcinoma; camrelizumab donafenib; transarterial chemoembolization ... See more keywords
Adjuvant donafenib for patients with hepatocellular carcinoma at high risk of recurrence following radical resection: A multi-center, retrospective study in China.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e15129
Abstract: e15129 Background: The implementation of adjuvant therapy in reducing tumor recurrence of hepatocellular carcinoma (HCC) is an essential approach for extending the prognosis of patients. The exploration of treatment strategies that are both efficacious and… read more here.
Keywords: donafenib; year; risk recurrence; group ... See more keywords
Adjuvant therapy with donafenib plus anti–PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e16228
Abstract: e16228 Background: There is no universally accepted standard treatment option or strategy for post-surgery adjuvant therapy for HCC. Among BCLC A/B patients with MVI, adjuvant TACE provided a 1-year recurrence-free survival rate (RFSR) of around… read more here.
Keywords: donafenib; risk; anti antibody; adjuvant therapy ... See more keywords
Donafenib plus hepatic arterial infusion chemotherapy and anti-PD-1 antibody therapies for unresectable hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e16172
Abstract: e16172 Background: Donafenib showed promising efficacy and safety in advanced hepatocellular carcinoma (HCC). But the efficacy of Donafenib plus hepatic arterial infusion chemotherapy (HAIC) and anti-PD-1 antibody (aPD1) therapies remained unknown. This study aimed to… read more here.
Keywords: donafenib; hepatic arterial; plus hepatic; arterial infusion ... See more keywords
The efficacy and safety of donafenib combined with anti–PD-1 antibody plus transarterial chemoembolization (TACE) as first-line treatment for patients (pts) with hepatocellular carcinoma (HCC): A retrospective study.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e16219
Abstract: e16219 Background: Transarterial chemoembolization (TACE), anti-angiogenic therapy, immune checkpoint inhibitor (ICI) therapy, and their combination strategies have an important role in decreasing tumor disease progression and improving survival in HCC patients. Donafenib has been approved… read more here.
Keywords: donafenib; therapy; tace; first line ... See more keywords
Postoperative adjuvant donafenib combined with PD-1 checkpoint inhibitor for patients at high risk of recurrence.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e16276
Abstract: e16276 Background: There is currently no internationally standardized adjuvant therapy for HCC patients with high-risk recurrence and metastasis after surgery, and the high risk of postoperative recurrence remains an unresolved issue. Therefore, the purpose of… read more here.
Keywords: donafenib; risk recurrence; risk; high risk ... See more keywords
Postoperative adjuvant therapy with donafenib in hepatocellular carcinoma with high-risk recurrence factors: A real-world, prospective, observational study.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e16316
Abstract: e16316 Background: The five-year recurrence rate of hepatocellular carcinoma (HCC) after hepatic resection is as high as 70% and remains a major clinical challenge. Although some reports have suggested adjuvant therapy to prevent HCC recurrence,… read more here.
Keywords: donafenib; hepatocellular carcinoma; adjuvant therapy; study ... See more keywords
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.00163
Abstract: PURPOSE Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study compared the efficacy and safety of donafenib versus sorafenib as… read more here.
Keywords: hepatocellular carcinoma; treatment; donafenib; first line ... See more keywords
AZ-628 sensitizes donafenib in hepatocellular carcinoma by targeting tyrosine kinase pathway and ferroptosis
Sign Up to like & getrecommendations! Published in 2025 at "CytoJournal"
DOI: 10.25259/cytojournal_273_2024
Abstract: Objective: Hepatocellular carcinoma (HCC) represents a primary liver tumor characterized by rapid disease progression and unfavorable clinical outcomes. Most patients with HCC are identified in advanced stage, where targeted therapies are considered an effective treatment… read more here.
Keywords: donafenib; resistance; hcc; tyrosine kinase ... See more keywords
The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Public Health"
DOI: 10.3389/fpubh.2022.794131
Abstract: Background Recent clinical trials have demonstrated that donafenib has superior efficacy and safety compared with sorafenib in Chinese patients with unresectable or metastatic hepatocellular carcinoma (HCC). The objective of this study was to assess the… read more here.
Keywords: cost; donafenib; compared sorafenib; unresectable metastatic ... See more keywords
Investigation into the Use of Surufatinib and Donafenib as Novel Multi-Kinase Inhibitors Therapeutic Agents in Managing Advanced Differentiated Thyroid Cancer: A Systematic Review
Sign Up to like & getrecommendations! Published in 2025 at "Biomedicines"
DOI: 10.3390/biomedicines13030752
Abstract: Background and Objectives: Differentiated thyroid cancer is the predominant form of endocrine cancer, with most cases being treatable. However, some patients develop resistance to traditional treatments. This review examines the use of the new multi-kinase… read more here.
Keywords: donafenib; cancer; differentiated thyroid; thyroid cancer ... See more keywords